This article summarizes selected patents in controlled release or delivery that were published from June 4, 2026 through August 13, 2026. Greater detail on each of these patents is given on the U.S. patent website PatentPublic Search | USPTO
General/Industrial Applications
US- 20260234456- MICROCAPSULES
Microcapsules with a shell encapsulating a thermotropic polymer in a liquid medium are disclosed, along with manufacturing methods and uses in products such as glazing coatings, providing temperature-responsive functional properties.
US- 20260232876- POROUS METAL STRUCTURES INCORPORATING NANOPARTICLES
Microcapsules having a shell surrounding an internal phase comprising a thermotropic polymer and liquid medium are described, including methods for making them and their use in products, particularly temperature-responsive coatings for glazing applications.
US- 20260201243- MICROCAPSULES FOR CONTROLLED RELEASE OF ACTIVES AGENTS, AND USE OF SAID MICROCAPSULES IN THE OIL AND GAS INDUSTRY
Microcapsules with a core containing an active agent and carrier, and a polymeric shell formed from (meth)acrylic ester copolymer and nanoclay. Preparation methods, use for controlled release, and a corrosion-prevention method in crude oil refineries are also disclosed.
US- 20260184858- MICROCAPSULE AND COMPOSITION EMPLOYING THE SAME
Microcapsules comprising a polyurea shell encapsulating 5–50 wt% organometallic promoter, the use of these microcapsules for controlled handling and delivery of the organometallic promoter are given.
US- 20260159743- MICROCAPSULES CONTAINING BIO-BASED AGENTS FOR DOWNHOLE APPLICATIONS IN OIL AND GAS INDUSTRY AND METHOD OF THEIR PRODUCTION
Well treatment compositions use microcapsules comprising a polymer shell encapsulating a bio-based agent and coated with a cationic macromolecule. Applications where capsules adhere, release the agent, and perform intended actions downhole are described.
Agriculture
US- 20260231931- CLOMAZONE MICROCAPSULES
Solid cross-linked biodegradable polymer microcapsules encapsulating clomazone are described with a mean diameter of 3–30 μm and a polymer wall thickness of 5–30% of the capsule diameter. Use in controlled delivery of clomazone for agricultural use is described.
US- 20260216323 - NANOPARTICLE-BASED ANTI-MYCOTOXIN VACCINES AND USES THEREOF
Nanoparticle–mycotoxin–hemocyanin complexes are described for vaccinating animals against mycotoxicosis by the oral route (in animal feed stock). A similar patent from the same inventor is given in US-20260217802.
Diagnostic/Sensing
US- 20260234468- FLUORESCENT NON-CONJUGATED POLYMER NANOPARTICLE WITH TANDEM DYES
Fluorescent tandem-dye nanoparticles based on non-conjugated polymer backbones with donor, FRET, acceptor dyes, and functional groups. Also described is the bioconjugation of antibodies to the particles for use in flow cytometry.
US- 20260235707- IMPLANTABLE BIOSENSOR CONTAINING A MAGNETIC NANOPARTICLE ASSAY FOR IN VIVO ANALYTE DETECTION
Description of an implantable biosensor containing functionalized magnetic nanoparticles in a biocompatible container and an external AC magnetic detection device. Analyte binding alters Néel relaxation, enabling noninvasive, quantitative in vivo analyte measurement.
US- 20260232805- METHODS FOR IMAGING USING SPCCT
A Spectral Photon Counting CT imaging method uses injectable nanoparticles (<10 nm) comprising a polyorganosiloxane matrix, covalently bound chelators, and chelated high-Z elements (Z≥40). After administration, SPCCT scans visualize anatomical structures with enhanced contrast.
US- 12704507- MULTIFUNCTIONAL MAGNETIC-OPTICAL NANOPARTICLES
Multifunctional nanoparticles are produced by forming magnetic nanoparticle clusters, coating them with water- soluble polymer, then associating them with quantum dots in a solvent polarity-driven process, yielding magnetic- optical nanoparticles.
US- 20260224739- FLUORESCENT EMISSION SPECTRAL STACKING OF POLYMER ENCAPSULATED QUANTUM DOTS
Polymer-encapsulated hydrophobic quantum dots with narrowly spaced emission peaks are described. Hydrophilic exteriors with functional groups enable antibody conjugates for multiplexed cellular analysis by spectral flow cytometry.
US- 20260227407- SYNTHETIC GLYCOPEPTIDES AND DERIVATIVES FOR THE EARLY-STAGE DETECTION OF CANCER BIOMARKERS IN MUC1-POSITIVE TUMORS
A MUC1-derived glycopeptide attached to nanoparticles is used as a pancreatic cancer biomarker by binding tumor-associated anti-MUC1 antibodies and a kit for detecting and quantifying anti-MUC1 antibodies in biological samples is provided.
US- 20260217920- COMPOSITE NANOPARTICLES, COMPOSITIONS THEREOF, AND METHODS OF USE AND MANUFACTURE
Composite nanoparticles comprising biodegradable amphiphilic copolymers (e.g., PEG-b-PCL, PEG-b-PLA, PEG-b- PLGA) and hydrophobic stable-isotope-labelled lipids (fatty acids, derivatives, lipid analogs) are disclosed.
US- 20260193724- METHOD FOR DETECTION OF SARS-COV-2 BY GOLD NANOPARTICLE ASSISTED LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) AND KITS THEREOF
A SARS-CoV-2 detection system uses RT-LAMP amplification followed by hybridization of amplicons with probe- functionalized gold nanoparticles. Kits comprising RT-LAMP enzymes, primers, and gold nanoparticle–probe conjugates specific to SARS-CoV sequences enable isothermal, nanoparticle-assisted viral detection.
US- 20260191997- CONJUGATES HAVING ANTIFOULING NANOPARTICLES AND METHODS OF USE
Conjugates comprising a small molecule linked to an antifouling nanoparticle with potential use in diagnosis, tissue imaging, temporal monitoring, and treatment while minimizing nonspecific interactions.
US- 20260153504- BIOSENSOR SYSTEM FOR DIAGNOSIS OF FAMILIAL MEDITERRANEAN FEVER(FMF) DISEASE
A portable plasmonic biosensor system for diagnosing Familial Mediterranean Fever includes a substrate, metal nanoparticles, ligand proteins, plasmonic chip, light source(s), spectrometer(s), and processing unit, enabling point-of-care FMF detection based on plasmonic signal changes.
Pharma
US- 20260232794 - IMMUNE COMPOSITION PRODUCT FOR PREVENTING OR TREATING VARICELLA ZOSTER VIRUS-RELATED DISEASES AND PREPARATION METHOD THEREFOR
A varicella-zoster vaccine comprises an antigenic component covalently linked via binding peptides to a nanoparticle protein component, forming an immunogenic complex.
US- 20260232836 - PEPTIDE-CONJUGATED LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS FOR BRAIN-TARGETED DELIVERY OF THERAPEUTIC AGENTS
Polypeptide-conjugated LNPs for brain-targeted delivery of therapeutic cargo that enable treatment, prevention, or amelioration of neurological diseases via peptide-directed crossing or targeting within the brain.
US- 20260232806 - COMPOSITIONS AND METHODS FOR TREATING WOUND HEALING AND HYPOTHERMIA
Nanoparticle-based delivery of adenyl cyclase activators (e.g., forskolin via LCMSN) is used to induce sWAT browning and thermogenesis, enhancing wound healing and protection from cold injuries.
US- 20260232813 - COMPOSITION AND METHOD OF USE FOR A THERAPEUTIC NANOLIGOMER
Therapeutic nanoligomers comprising PNA with a polypeptide backbone (including 2-N-aminoethylglycine units) and a transport domain with delivery nanoparticle and cellular uptake domain.
US- 20260234115 - LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF
Novel lipid compounds and LNP compositions containing them are provided for delivering active agents, including polynucleotides, to cells, preferably extrahepatic tissues.
US- 20260232839 - LIPID NANOPARTICLE, PHARMACEUTICAL COMPOSITION, AND METHOD FOR PRODUCING LIPID NANOPARTICLE
LNPs encapsulating a protein (antibody or fragment) with a polymer opposite in charge at a defined pH are disclosed. Preferred particle sizes have peaks at 80–120 nm.
US- 20260232601 - COMPOSITIONS AND METHODS FOR DELIVERING CARGO TO CELLS
Functionalized polyethylenimine compounds form nanoparticles for tissue-specific delivery of diverse cargo. Methods for synthesis, nanoparticle formation, and cell-specific cargo delivery with low toxicity are provided.
US- 20260232837 - LIPID NANOPARTICLE WITH NON-COVALENT BIFUNCTIONAL BINDERS FOR ACTIVE TARGETING
A nanoparticle complex comprises a bifunctional binder capable of non-covalently binding to the lipid nanoparticle in the nanoparticle complex.
US- 20260226138 - COMBINATION TUMOR THERAPY WITH THROMBOSIS INITIATION AND PLATELET RECRUITMENT
A solid-tumor therapy administers a fusion polypeptide (tissue factor fragment plus tumor vessel endothelial- binding peptide) to induce localized coagulation, followed by platelet cells or platelet-membrane-coated chemotherapeutic nanoparticles bearing immune checkpoint inhibitors.
US- 20260224738 - MICELLE NANOPARTICLES COMPRISING BIOPOLYMER-HEMIN COMPLEX, AND USE THEREOF
Self-assembled micelle nanoparticles from hydrophilic biopolymer–hydrophobic hemin complexes form core–shell structures, exhibiting catalase- and superoxide dismutase-like activities, enabling treatment, prevention, or alleviation of inflammatory diseases via reactive oxygen species modulation.
US- 20260224491 - MICROSPHERES COMPRISING HIGH-DOSE VARENICLINE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Microspheres containing high-concentration varenicline hemipamoate in a biocompatible polymer matrix exhibit controlled initial and sustained release, maintaining effective blood levels over extended periods with reduced side effects.
US- 20260224733 - NANOPARTICLES DIRECTED TO CXCR4 AND USE THEREOF
Nanoparticles with surfaces covalently conjugated to AMD3100 or derivatives bind CXCR4. Methods for treating CXCR4-positive cancers (e.g., multiple myeloma, AML) are given.
US- 20260216338 - CLAY NANOPARTICLES FOR MEDICAL USE
Medical compositions comprise clay nanoparticles with an anionic component and a cationic component. These engineered clays are suitable for various therapeutic or diagnostic applications.
US- 20260216072 - COMPOSITION
LNP compositions comprising an active ingredient and a lipid mixture with an ionizable cationic lipid, steroid, and negatively charged amphiphile are described.
US- 20260216087 - NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY
New ionizable lipids for forming nanoparticles with phospholipids, structural lipids, and PEG lipids are described. These nanoparticles encapsulate biologically active agents (e.g., siRNA, mRNA) for therapeutic applications.
US- 20260216319 - IMMUNOGENIC COMPOSITIONS AND METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST VARICELLA ZOSTER VIRUS
Immunogenic compositions comprising RNA molecules encoding VZV antigens formulated in LNPs are used to induce immune responses in humans, enabling prevention or treatment of varicella-zoster virus infections, including herpes zoster.
US- 20260216071 - NANOPARTICULATE FORMULATION
Nanolipogels and biodegradable polymeric nanoparticles (e.g., PLGA) carrying at least one immunomodulator plus additional active agents are described. Targeting moieties may decorate particles to enhance delivery and treat diseases such as cancer.
US- 20260216070 - COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF NUCLEIC ACID-BASED THERAPEUTICS AND METHODS THEREOF
Various compounds are disclosed as components of LNPs for delivering biological/therapeutic agents along with LNP compositions, manufacturing and delivery methods for nucleic acid-based therapeutics are described.
US- 20260217768 - NANOPARTICLE-NHE3 PEPTIDE TO TREAT DIARRHEA
Disclosed are NHE3 mimetic peptides and their conjugates with a reporter molecule or a carboxylated, branched poly(β-amino ester) (PBAE) nanoparticle and their use for treating diarrhea.
US- 20260217645 - AMINO LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
An amino lipid compound, and a preparation method of a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound.
US- 20260217772 - ENGINEERED PARAMYXOVIRUS SOLUBLE FUSION (F) PROTEINS AND RELATED VACCINES
Stabilized soluble F proteins from paramyxoviruses (RSV, hMPV, hPIV) with specific sequence modifications are presented. These immunogens are displayed on self-assembling nanoparticles to create vaccines for preventing or treating viral infections.
US- 20260218151 - METHOD OF DELIVERING NUCLEIC ACID TO T CELLS AND COMPOSITIONS FOR USE THEREOF
Methods deliver nucleic acids to T cells using LNPs containing 30–70 mol% neutral/zwitterionic lipid, ionizable cationic lipid, and sterol, with neutral physiological charge.
US- 20260217744 - BRANCHED PHOSPHOLIPIDS
The application is related to compounds of Formula I, their uses and lipid nanoparticle formulations
US- 20260209803 - COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID
LNP-based compositions encapsulate targetable nucleases, nucleic acids, nucleic acid-binding proteins/mRNA, and donor templates with HDR sequences and binding sites. Cas proteins and sgRNAs can be included in the system as well.
US- 20260207529 - NANOFIBER CARRIER AND ITS PREPARATION METHOD
Electrospun nanofiber carriers composed of biocompatible polymers, inorganic salts, and bioactive agents form 3D, dynamically stable structures enabling rapid, uniform, and controlled release. Applications include drug, biomolecule, gene, cell transport, nanoparticle release, tissue repair, cosmetics, and industrial uses.
US- 20260207526 - LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS
Lyophilized nucleic acid LNPs (NALNPs) comprising LNP-encapsulated nucleic acid and a lyophilization buffer (sugar, reagent, diluent) are disclosed.
US- 20260207525 - LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS, IONIZABLE LIPIDS, STEROLS, LIPID ANCHORED POLYMERS AND HELPER LIPIDS, THEIR USES
LNP compositions containing therapeutic nucleic acids, ionizable lipid, helper lipid (e.g., ceramide, DSPC), structural sterol, and lipid-anchored polymers are given here.
US- 20260207736 - HEPATITIS B COMPOSITIONS
A composition for treating chronic hepatitis B infection comprising mRNA encoding a hepatitis B virus antigen, wherein the mRNA is encapsulated in a lipid nanoparticle (LNP).
US- 20260207504 - STABILIZATION OF LIPID NANOPARTICLE FORMULATIONS
Compositions and methods reduce lipid nanoparticle degradation (oxidation, hydrolysis), often via histidine buffers, improving LNP and API stability.
US-20260207758- NANOPARTICLE COMPRISING PEPTIDE-BASED CONJUGATE FOR DELIVERING MRNA INTO B CELL AND T CELL AND USES THEREOF
Peptide-based conjugates bind mRNA via RNA-binding peptides and self-assemble with amphipathic components into nanoparticles, efficiently delivering mRNA to immune cells
US-20260207527- STABILIZED LIPID NANOPARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS
A stabilized lipid nanoparticle includes mRNA and a compound comprising formula (I):
US-20260207770- MEMBRANE COATED NANOPARTICLES FOR MODULATING AN IMMUNE RESPONSE
Nanoparticles coated with membranes from antigen-presenting cells form compositions for modulating immune responses in vitro or in vivo, enabling immunotherapy and immune modulation applications.
US-20260207650- PROLIFERATION INHIBITOR OF BREAST CANCER CELLS AND THERAPEUTIC AGENT FOR BREAST CANCER
An mRNA molecule (zapomeran) encoding a spike glycoprotein-binding sequence, preferably LNP-encapsulated, is used as a proliferation inhibitor and therapeutic agent for breast cancer cells expressing ACE2.
US- 20260199387- ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS FOR THERAPY OF HEPATOCELLULAR CARCINOMA
LNPs selectively delivering nucleic acids encoding CARs, T-cell engagers, and/or therapeutic genes to M2 macrophages convert HCC-associated macrophages to antitumor M1 types for treating hepatocellular carcinoma.
US- 20260201384- PHARMACEUTICAL COMPOSITION COMPRISING SIRNA AND A METHOD OF PREPARING THE SAME
Pharmaceutical compositions comprise siRNA targeting BLIMP1 beta mRNA for autoimmune disease treatment in formulations that include siRNA, nanoparticle, cell-targeting moiety, and PEG.
US- 20260199450- NUCLEIC ACID-LIPID NANOPARTICLE SUITABLE FOR INTRAMUSCULAR ADMINISTRATION, PREPARATION THEREOF, AND USE THEREOF
Nucleic acid LNPs optimized for intramuscular use include 20–35 mol% ionizable lipid, 15–30 mol% non-ionizable cationic lipid, 0–10 mol% neutral phospholipid, 40–56 mol% cholesterol, and 1.5–3 mol% PEG-lipid, encapsulating mRNA or plasmid DNA.
US- 20260199449- MULTIVALENT INFLUENZA MRNA VACCINES
Multivalent influenza mRNA vaccines encapsulated in LNPs encode at least three HA antigens from influenza A and B, with differing A/B mRNA ratios, to elicit broad immune responses against multiple influenza strains.
US- 20260199239- IONIZABLE LIPIDS WITH MALONATE TAILS
Ionizable lipids featuring a central nitrogen with head group and two biodegradable hydrophobic tails, at least one containing a malonate moiety, are described for LNP formulations delivering therapeutic agents such as mRNA.
US- 20260199514- PRODRUG STRATEGY THAT ENHANCES EFFICACY AND LOWERS SYSTEMIC TOXICITY OF MERTANSINE
Nanoparticles incorporate prodrug components: targeting moiety–lipid, PEG-lipid, sterol, bulk lipid, and drug–lipid conjugate with cleavable linker used in cancer treatments such as multiple myeloma.
US- 20260199520- LIPID NANOPARTICLE MODIFIED WITH A TARGETING MOIETY FOR TARGETED DELIVERY
LNPs encapsulating nucleic acids contain ≥30 mol% neutral lipid and sterol, with targeting moieties anchored via lipophilic groups. These designs improve in vivo targeting and delivery to extrahepatic tissues/organs.
US- 20260201348- CARBON ANTIOXIDANT ENZYME MIMIC, ANTI-INFLAMMATORY COMPOSITION COMPRISING THE SAME, AND METHOD FOR PREPARING THE SAME
Carbon nanoparticle-based enzyme mimics bearing carbonyl/amine and hydroxyl surface groups scavenge ROS and RNS without metal ions, reducing inflammatory cytokines and increasing endogenous antioxidant enzymes, enabling anti-inflammatory therapeutic compositions.
US- 20260200849- CATIONIC LIPIDS AND PREPARATION METHOD THEREOF
Novel cationic lipids, methods for their synthesis, and LNP formulations containing these lipids for nucleic acid delivery in vitro and in vivo.
US- 20260199516- COMPOSITIONS AND METHODS FOR DELIVERY OF DNA TO T CELLS
Targeted LNPs bearing T-cell antigen-binding moieties deliver double-stranded DNA (with or without modifications) with effector-encoding sequences to T cells.
US- 20260191779- MITOCHONDRIAL-ENDOPLASMIC RETICULUM CELL DEATH INDUCING NANOPARTICLES
Nanoparticle formulations combine three agents: one disrupting mitochondrial networks and ER association, one inducing ER stress/unfolded protein response, and one activating mitochondrial apoptosis, synergistically killing multidrug-resistant cancers such as triple-negative breast cancer.
US- 20260191987- GENE CARRIER BASED ON METAL NANO PARTICLE-NUCLEIC ACID CONJUGATE
A gene carrier including a nucleic acid molecule containing a gene of interest conjugated to the surface of a metal nanoparticle, which is delivered into cells and expressed.
US- 20260191785- TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF
Taste-masking microspheres comprise 1.5–21.2 parts drug, 35–110 parts carrier, alkalizing agent and plasticizer.
US- 20260193172- CYCLOALKANE-BASED LIPID COMPOUND FOR DELIVERING NUCLEIC ACIDS, AND LIPID NANOPARTICLES COMPRISING SAME
Cycloalkane-based ionizable lipids having carbonyl substituents on a cycloalkane core are described as LNP components for nucleic acid delivery.
US- 20260193175- ALKANOLAMINE MULTI-TAILED LIPID, PREPARATION METHOD THEREFOR, AND USE THEREOF
Multi-tailed alkanolamine ionizable lipids with simple, scalable synthesis maintain LNP stability and delivery efficiency with high efficacy and low toxicity. They can bind mRNA via hydrogen bonding/van der Waals even at neutral pH.
US- 20260183240- LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO
LNPs encapsulating nucleic acids (mRNA) contain cationic lipids, stabilizers including PEG-lipids, and GDGT lipids (e.g., from Sulfolobus), improving stability and potentially mimicking archaeal membrane features for vaccines.
US- 20260184669- NANOPARTICLE-OLIGOT CONJUGATES BASED MESSENGER RNA DELIVERY SYSTEM
Gene carriers comprising nanoparticles decorated with oligo-T sequences bind poly(A)-tailed nucleic acids enabling efficient cellular delivery of target genes.
US- 20260183382- LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE
Novel lipid compounds for LNPs enhance multivalent binding and encapsulation of active substances, improving structural stability, intracellular delivery, and biological activity for disease treatment and prevention.
US- 20260183420- ACTIVATED NANOTHERAPY FOR SICKLE CELL DISEASE
Composite nanoparticles combining two 5-HMF prodrugs (5-HMF-grafted phospholipid over sucrose-derived graphitic carbon dot core) target RBCs, delivering antisickling agent with improved potency, targeting, and sustained release for sickle cell disease therapy.
US- 20260183247- GENE DELIVERY NANOPARTICLE, AND PREPARATION AND APPLICATION THEREOF
Polyethylene glycol–poly(sparfloxacin) copolymers, prepared via RAFT polymerization and subsequent conjugation, self-assemble into nanoparticles in aqueous solution, serving as gene delivery vehicles in biomedical applications.
US- 20260174841- METHODS AND COMPOSITIONS OF QUATERNARY IMMUNOMODULATORY NANOPARTICLES FOR MEDICAL APPLICATIONS AND IMMUNOTHERAPY
Quaternary immunomodulatory nanoparticles (QINs) act as immune modulators administered with antigens to enhance immune responses. Uses include chimeric nanoparticles, pharmaceutical compositions, and treatments for cancers or viral infections.
US- 20260174694- LIPID NANOPARTICLE FORMULATIONS FOR ANTI-SENSE OLIGONUCLEOTIDE DELIVERY
LNPs encapsulate single- or double-stranded oligonucleotides (5–500 nt) and comprise 20–70 mol% neutral lipids, ionizable lipids, sterols, and optionally hydrophilic polymer–lipid conjugates, enabling oligonucleotide delivery.
US- 20260176625- LIPID NANOPARTICLES WITH BLEBS HAVING IMPROVED TRANSFECTION EFFICIENCY
Methods produce nucleic acid LNPs with bleb compartments by mixing high-concentration, low-pH aqueous buffer with lipid solution containing ionizable and helper lipids, then exchanging external solution to higher pH. Resulting blebbed LNPs.
US- 20260174706- LIPID NANOPARTICLE FORMULATION FOR TRANSPULMONARY DELIVERY OF NUCLEIC ACID DRUGS AND USE THEREOF
LNP compositions optimized for transpulmonary delivery demonstrate lung- and cell-specific targeting with high biocompatibility.
US- 20260174882- PREPARATION OF LIPID NANOPARTICLE (LNP) CONJUGATES
Conjugates of LNPs encapsulating therapeutic agents with targeting moieties via thiol-containing linkers and click chemistry for directed delivery.
US- 20260166197- SILVER HYDROGEL BIOCERAMIC COMPOSITIONS FOR DENTAL AND MEDICAL APPLICATIONS
Premixed pastes comprising silver nanoparticles/ions, hydrogel former, hydratable bioceramic, and hydrophilic non-aqueous carrier are described for dental/medical uses.
US- 20260166148- MAGNETOSTRICTIVE PIEZOELECTRIC NANOASSEMBLY AS CANCER CHEMOTHERAPEUTIC
Multifunctional nanoassemblies with magnetostrictive cores, piezoelectric elements, dextran-iron oxide, quantum dots, photosensitizers, aptamers, and optional ¹⁸F-FDG perform cancer therapy via magnetically induced heat, ROS generation, and immunological factor release, with concurrent imaging capabilities.
US- 20260165968- SUSTAINED-RELEASE PLGA MICROSPHERE CONTAINING GS-441524, AND METHOD FOR PRODUCING SAME
GS-441524-loaded PLGA microspheres provide sustained release over about one week, enabling stable, continuous drug supply, improved patient compliance, and reduced treatment costs.
US- 20260166149- NEAR-INFRARED RESPONSIVE BILIRUBIN COMPOSITE NANOPARTICLE-LOADED PERIODONTAL MICRONEEDLE AND PREPARATION METHOD THEREOF
Near-infrared-responsive bilirubin–gelatin composite nanoparticles coated with macrophage membrane and anthocyanin–Fe supramolecular network, surface-modified with DSPE-PEG-FA, are integrated into periodontal microneedle.
US- 20260165979- LIPID NANOPARTICLES
C-glycoside glycolipid compounds as LNP components with potential use in LNP formulations and vaccines for enhanced immunogenicity or delivery.
US- 20260165980- LYMPHATIC ENDOTHELIAL CELL-SPECIFIC LIPID NANOPARTICLE AND USES THEREOF
LEC-specific LNPs comprising sterol, ionizable lipid, PEGylated lipid, and phospholipid for targeted delivery to lymphatic systems.
US- 20260166176- POLYMER-NUCLEIC ACID NANOPARTICLES FOR GENE EDITING
CRISPR adenine base editing corrected CFTR CSSV c.2988+1G>A in airway cells, restoring >50% function. Polymeric nanoparticles delivered mRNA with high transfection and viability in HBE/HNE cells, supporting translational in vivo gene editing using optimized polymeric nanoparticles.
US- 20260157965- GOLD NANOPARTICLE COMPOSITION AND USES THEREOF
Compositions include gold nanoparticles encapsulated within liposomes containing heme. Uses include cancer treatment and induction of lipid oxidation, membrane potential changes, and ROS generation.
US- 20260158161- AN ADJUVANT AND CD47-BLOCKADE COMBINATION CANCER TREATMENT AND METHODS OF USING THE SAME
Nanoparticle adjuvants bearing cancer-binding molecules and SLAMF7 decorate cancer cells to promote antigen- presenting cell binding and phagocytosis in combination with a CD47 blockade for antitumor immunity.
US- 20260158165- POLYPHENOL LIPID NANOPARTICLES AND METHODS OF USE
LNPs containing ionizable lipid, phospholipid, sterol, PEG lipid, and polyphenol (0.5–15 mol%) are disclosed with improved endosomal escape. Methods for nanoparticle preparation and delivery of cargo are described.
US- 20260157974- DRUG-RELEASING NANOPARTICLE-ENHANCED HYDROGEL, PREPARATION METHOD THEREFOR, AND USE THEREOF
Porous hydrogels crosslinked from acrylated biodegradable polymers are loaded with phospholipid–acrylate polymer-encapsulated drug nanoparticles, enabling >90% drug release over 4–72 hours, improving wound healing, re-epithelialization, angiogenesis, collagen regeneration, and minimizing scarring.
US- 20260151347- CELL-DERIVED MICROPARTICLE DELIVERY SYSTEM AND USES THEREOF
Microparticles comprising a core surrounded by cell membrane-derived shells are provided. Methods include binding these microparticles to endothelia and transporting them across an endothelial barrier.
US- 20260151504- SYNTHETIC CELLS COMPRISING TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) AND METHODS OF USING THE SAME
Synthetic cytotoxic “cells” consist of TRAIL or fragments attached to hydrogel microspheres. Preparation and therapeutic use against cancer are described.
US- 20260151651- INTERFERENCE SYSTEM COMPRISING AT LEAST TWO SOURCES OF RADIATION EMITTING TWO BEAMS OF RADIATION INTERFERING IN A BODY PART OR REGION TO BE TREATED AND AT LEAST ONE NANOPARTICLE
A radiation-heating system uses at least two oriented radiation sources creating an interference region containing nanoparticles leading to heating in the target body region enables therapeutic applications.
Bio
US-20260234673- RESPIRATION OF NANOPARTICLES BY ELECTROGENIC BACTERIA FOR PHOTO-CATALYTIC HYDROGEN EVOLUTION
Hydrogen evolution systems combine light-absorbing nanoparticles (e.g., cadmium chalcogenide quantum dots, nanorods, nanoplatelets) with electrogenic bacteria (e.g., Shewanella, Geobacter) in aqueous media. Bacteria replenish electrons to nanoparticles which, upon illumination, reduce protons to hydrogen.
US-20260216248- CELL-MICROSPHERE CO-ASSEMBLY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Co-assemblies of hydrogel microspheres and cells (0.0001–10 μL microspheres per 10¹–10⁷ cells) enhance cell paracrine effects. Injectable into damaged tissues, they promote repair of injured cells.
US-20260209062- METHOD FOR PRODUCING METAL OXIDE NANOPARTICLES AND METAL OXIDE NANOPARTICLES PRODUCED THEREBY
A shortened aging process produces metal oxide nanoparticles (e.g., cerium oxide) with oxygen-deficient surfaces and enhanced SOD activity within days instead of weeks, enabling industrial-scale production for biomedical applications.
US-20260209708- MOLECULAR NANOPARTICLE MICROCARRIERS AND RELATED METHODS
Molecular nanoparticle microcarriers (M@PDNPs-siRNAs) are produced by generating CXCR4/PSGL-1- overexpressing MSC vesicles, preparing siRNA-loaded polypeptide dendrimer nanoparticles, and extruding them together, yielding targeted siRNA delivery vesicles.
US-20260209689- MICROCAPSULE CROSSLINKING
Methods for gently forming hydrogel microcapsules reduce adverse crosslinking effects on encapsulated contents (e.g., cell populations).
US-20260183381- FREEZE-DRYING PROTECTIVE AGENT FOR NUCLEIC ACID-LIPID NANOPARTICLES, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Optimized freeze-drying processes and protective agents for nucleic acid LNPs reduce lyophilization time to 8–18 hours, preserving nucleic acid content, encapsulation, integrity, rapid rehydration, transfection efficiency, and in vivo immunogenicity.
US-20260167972- AMINO ACID DERIVATIVES AS NOVEL DELIVERY AGENTS FOR FUNCTIONAL DELIVERY OF OLIGONUCLEOTIDES
Nanoparticle complexes of siRNA with amino acid derivatives form spherical, micelle-like, sheet, or fibril-like structures. They deliver RNA/DNA to cells, achieving ≥50% knockdown with ≥40% cell viability in 48 hours.
US-20260165971- SINGLE-CELL MICROSPHERE PREPARED BASED ON OIL-FREE AQUEOUS TWO-PHASE SYSTEM STRATEGY AND PREPARATION METHOD THEREFOR
An oil-free aqueous two-phase system allows gravity-driven transfer of single cells into hydrogel-containing phase, encapsulating individual cells into microspheres without oils/surfactants.
US-20260151349- COMPOSITIONS AND METHODS FOR AUGMENTING BIOHYBRID CHEMICAL SENSOR PERFORMANCE THROUGH NANO-NEUROMODULATION
Functionalized nanoparticles with mesoporous coatings contain neurally active compounds and phase-change materials. Heating results in controlled release to modulate neural activity, enhancing biohybrid chemical sensor performance or brain organoid responses.
Consumer Products/ Cosmetics
US- 20260232748- COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING CHIA SEED MUCILAGE
Chia seed mucilage-based gels and microencapsulation creams show antibacterial activity and modulate the hair cycle by inhibiting apoptosis and enhancing metabolism, promoting follicle neogenesis and hair growth.
US- 20260226377- BIODEGRADABLE MICROCAPSULES CONTAINING LOW LOG P FRAGRANCE
White core–shell microcapsule slurries contain active cores with 3–18 wt% low logP fragrance and shells of self- condensed polyisocyanate, denatured pea protein dispersant and gum Arabic, for biodegradable fragrance delivery systems.
US- 12691061- CAFFEINE-FREE READY-TO-DRINK COMPOSITION FOR PRE-CAFFEINE COGNITIVE PRIMING
A 2–3 oz caffeine-free drink (pH 3.0–3.5) containing N-acetyl L-tyrosine, citicoline, phosphatidylserine, adaptogens, L-citrulline, piperine, B6, B12, magnesium, and specific acids primes cognition pre-caffeine. Packaging and microencapsulation address stability and flavor.
US- 20260207445- IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS
Core–shell microcapsules with hydrophobic cores and shells formed by enzyme-catalyzed in situ polymer/oligomer formation are disclosed, providing environmentally friendly microencapsulation for various benefit agents.
US- 20260201285- MICROCAPSULES
Core–shell microcapsules have an inner shell with benefit agent and an outer shell of crosslinked polysaccharide formed via oligofunctional (meth)acrylate crosslinkers.
US- 20260192274- MICROCAPSULE AND METHOD
Perfume-containing microcapsules with cores of perfume and shells comprising plant protein plus polysaccharide (e.g., pectin, celluloses, gums, alginate, gellan, carrageenan) are produced without covalent crosslinking.
US- 20260191747- ORAL CARE NANOPARTICLE COMPOSITIONS AND METHODS
Oral care compositions contain spherical and/or coral-shaped nanoparticles plus stabilizer, formulated into carriers such as mouthwash or dentifrice. The nanoparticles modulate local pH to prevent/treat oral conditions, supplied as stable concentrates for various oral products.
US- 20260183624- GOLF CLUB HEAD COMPRISING MICROSPHERES
A putter head with a cast urethane face insert incorporating glass microspheres. Microspheres are non-uniformly distributed for tailored impact properties.
US- 20260174640- SUNSCREEN FORMULATION COMPRISING MICROCAPSULES, AND PROCESS FOR MANUFACTURING SUCH MICROCAPSULES
Submicron core–shell microcapsules (shell ≥20 wt% of capsule) with crosslinked polymer shells (from interfacial polymerization) encapsulate actives such as sunscreens.
US- 20260176557- FABRIC AND HOME CARE COMPOSITIONS
Fabric/home care formulations contain polyester soil release polymers with high ethylene glycol-to-terephthalate ratios and perfume microcapsules with acrylate shells and benefit-agent cores, improving soil release and fragrancing performance.
Observations/Thoughts/Trends/Musings
You may recall, dear Reader, that my last patent review article was uncharacteristically short. I’m happy to report that this document returns to the previous form that can only be described as “tediously long.” While you may not appreciate this return of length, I myself am encouraged (“We’re back baby!”). After being re-energized by attending the annual meeting in Portugal, where I had the pleasure of judging posters exhibiting some truly outstanding work, this glut of patents in the realm of controlled release just further illustrates the fertile soil of our field of study. Enjoy the doldrums of summer (for those on the top half of our planet), and I’ll catch you at the next one.
K
